Intrahepatic Cholestasis

Textbook of Hepatology: From Basic Science to Clinical Practice, Third Edition

Volumn , Issue , 2008, Pages 1479-1500

  Chazouillères, Olivier ^a,b   Housset, Chantal ^a,b,c  

^a SORBONNE UNIVERSITÉ   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c HÔPITAL TENON   (France)

Author keywords

Bile canaliculi; Biliary secretion; Extrahepatic tissues; Intrahepatic cholestasis

Indexed keywords

EID: 84889274170     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470691861.ch19a     Document Type: Chapter

References (132)

1. Trauner M, Wagner M, Fickert P et al. (2005) Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis. J Clin Gastroenterol 39, S111-124.
2. Pauli-Magnus C, Meier PJ (2005) Hepatocellular transporters and cholestasis. J Clin Gastroenterol 39, S103-110.
3. Fouassier L, Kinnman N, Lefevre G et al. (2002) Contribution of mrp2 in alterations of canalicular bile formation by the endothelin antagonist bosentan. J Hepatol 37, 184-191.
4. Lakehal F, Dansette PM, Becquemont L et al. (2001) Indirect cytotoxicity of flucloxacillin toward human biliary epithelium via metabolite formation in hepatocytes. Chem Res Toxicol 14, 694-701.
5. Anderson JM (1996) Leaky junctions and cholestasis: a tight correlation. Gastroenterology 110, 1662-1665.
6. Kawaguchi T, Sakisaka S, Sata M et al. (1999) Different lobular distributions of altered hepatocyte tight junctions in rat models of intrahepatic and extrahepatic cholestasis. Hepatology 29, 205-216.
7. Rahner C, Stieger B, Landmann L (1996) Structure-function correlation of tight junctional impairment after intrahepatic and extrahepatic cholestasis in rat liver. Gastroenterology 110, 1564-1578.
8. Kawaguchi T, Sakisaka S, Mitsuyama K et al. (2000) Cholestasis with altered structure and function of hepatocyte tight junction and decreased expression of canalicular multispecific organic anion transporter in a rat model of colitis. Hepatology 31, 1285-1295.
9. Lora L, Mazzon E, Martines D et al. (1997) Hepatocyte tightjunctional permeability is increased in rat experimental colitis. Gastroenterology 113, 1347-1354.
10. Sakisaka S, Kawaguchi T, Taniguchi E et al. (2001) Alterations in tight junctions differ between primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology 33, 1460-1468.
11. Fickert P, Fuchsbichler A, Wagner M et al. (2004) Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 127, 261-274.
12. Bolder U, Ton-Nu HT, Schteingart CD et al. (1997) Hepatocyte transport of bile acids and organic anions in endotoxemic rats: impaired uptake and secretion. Gastroenterology 112, 214-225.
13. Trauner M, Arrese M, Soroka CJ et al. (1997) The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis. Gastroenterology 113, 255-264.
14. Green RM, Beier D, Gollan JL (1996) Regulation of hepatocyte bile salt transporters by endotoxin and inflammatory cytokines in rodents. Gastroenterology 111, 193-198.
15. Spirli C, Nathanson MH, Fiorotto R et al. (2001) Proinflammatory cytokines inhibit secretion in rat bile duct epithelium. Gastroenterology 121, 156-169.
16. Chen F, Ananthanarayanan M, Emre S et al. (2004) Progressive familial intrahepatic cholestasis, type 1, is associated with decreased farnesoid X receptor activity. Gastroenterology 126, 756-764.
17. Makishima M, Okamoto AY, Repa JJ et al. (1999) Identification of a nuclear receptor for bile acids. Science 284, 1362-1365.
18. Parks DJ, Blanchard SG, Bledsoe RK et al. (1999) Bile acids: natural ligands for an orphan nuclear receptor. Science 284, 1365-1368.
19. Ananthanarayanan M, Balasubramanian N, Makishima M et al. (2001) Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J Biol Chem 276, 28857-28865.
20. Denson LA, Sturm E, Echevarria W et al. (2001) The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp. Gastroenterology 121, 140-147.
21. Chiang JY, Kimmel R, Weinberger C et al. (2000) Farnesoid X receptor responds to bile acids and represses cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription. J Biol Chem 275, 10918-10924.
22. Pircher PC, Kitto JL, Petrowski ML et al. (2003) Farnesoid X receptor regulates bile acid-amino acid conjugation. J Biol Chem 278, 27703-27711.
23. Barbier O, Torra IP, Sirvent A et al. (2003) FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity. Gastroenterology 124, 1926-1940.
24. Neimark E, Chen F, Li X et al. (2004) Bile acid-induced negative feedback regulation of the human ileal bile acid transporter. Hepatology 40, 149-156.
25. Huang L, Zhao A, Lew JL et al. (2003) Farnesoid X receptor activates transcription of the phospholipid pump MDR3. J Biol Chem 278, 51085-51090.
26. Sinal CJ, Tohkin M, Miyata M et al. (2000) Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102, 731-744.
27. Staudinger JL, Goodwin B, Jones SA et al. (2001) The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci USA 98, 3369-3374.
28. Liu Y, Binz J, Numerick MJ et al. (2003) Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra-and extrahepatic cholestasis. J Clin Invest 112, 1678-1687.
29. Frijters CM, Ottenhoff R, van Wijland MJ et al. (1997) Regulation of mdr2 P-glycoprotein expression by bile salts. Biochem J 321(Pt 2), 389-395.
30. Gupta S, Todd Stravitz R, Pandak WM et al. (2000) Regulation of multidrug resistance 2 P-glycoprotein expression by bile salts in rats and in primary cultures of rat hepatocytes. Hepatology 32, 341-347.
31. Folli F, Alvaro D, Gigliozzi A et al. (1997) Regulation of endocytic-transcytotic pathways and bile secretion by phosphatidylinositol 3-kinase in rats. Gastroenterology 113, 954-965.
32. Misra S, Ujhazy P, Gatmaitan Z et al. (1998) The role of phosphoinositide 3-kinase in taurocholate-induced trafficking of ATPdependent canalicular transporters in rat liver. J Biol Chem 273, 26638-26644.
33. Wagner M, Fickert P, Zollner G et al. (2003) Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. Gastroenterology 125, 825-838.
34. Alpini G, Lenzi R, Sarkozi L et al. (1988) Biliary physiology in rats with bile ductular cell hyperplasia. Evidence for a secretory function of proliferated bile ductules. J Clin Invest 81, 569-578.
35. Masyuk TV, Ritman EL, LaRusso NF (2001) Quantitative assessment of the rat intrahepatic biliary system by three-dimensional reconstruction. Am J Pathol 158, 2079-2088.
36. Beaussier M, Wendum D, Fouassier L et al. (2005) Adaptative bile duct proliferative response in experimental bile duct ischemia. J Hepatol 42, 257-265.
37. Alpini G, Glaser SS, Ueno Y et al. (1999) Bile acid feeding induces cholangiocyte proliferation and secretion: evidence for bile acidregulated ductal secretion. Gastroenterology 116, 179-186.
38. Chignard N, Mergey M, Barbu V et al. (2005) VPAC1 expression is regulated by FXR agonists in the human gallbladder epithelium. Hepatology 42, 549-557.
39. Chignard N, Mergey M, Veissiere D et al. (2001) Bile acid transport and regulating functions in the human biliary epithelium. Hepatology 33, 496-503.
40. Chignard N, Mergey M, Veissiere D et al. (2003) Bile salts potentiate adenylyl cyclase activity and cAMP-regulated secretion in human gallbladder epithelium. Am J Physiol Gastrointest Liver Physiol 284, G205-212.
41. Portmann BC, MacSween RNM (1994) Diseases of the intrahepatic bile ducts. In: MacSween RNM, Anthony PP, Scheuer PJ et al. (eds) Pathology of the Liver. Edinburgh: Churchill Livingstone, pp. 477-512.
42. Scheuer PJ, Lefkowitch JH (2000) Assessment and differential diagnosis of pathological features. In: Saunders WB (ed) Liver Biopsy Interpretation. London: Harcourt Publishers Ltd, pp. 51-65.
43. Desmet VJ (1986) Current problems in diagnosis of biliary disease and cholestasis. Semin Liver Dis 6, 233-245.
44. Roskams TA, Theise ND, Balabaud C et al. (2004) Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology 39, 1739-1745.
45. Lefkowitch JH (2004) Histological assessment of cholestasis. Clin Liver Dis 8, 27-40, v.
46. Li MK, Crawford JM (2004) The pathology of cholestasis. Semin Liver Dis 24, 21-42.
47. Ludwig J, Wiesner RH, LaRusso NF (1988) Idiopathic adulthood ductopenia. A cause of chronic cholestatic liver disease and biliary cirrhosis. J Hepatol 7, 193-199.
48. Moreno A, Carreno V, Cano A et al. (1997) Idiopathic biliary ductopenia in adults without symptoms of liver disease. N Engl J Med 336, 835-838.
49. Demetris A, Adams D, Bellamy C et al. (2000) Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel. Hepatology 31, 792-799.
50. Devaney K, Goodman ZD, Epstein MS et al. (1993) Hepatic sarcoidosis. Clinicopathologic features in 100 patients. Am J Surg Pathol 17, 1272-1280.
51. Hubscher SG, Lumley MA, Elias E (1993) Vanishing bile duct syndrome: a possible mechanism for intrahepatic cholestasis in Hodgkin's lymphoma. Hepatology 17, 70-77.
52. Viguier B (2004) Functional adaptations in the craniofacial morphology of Malagasy primates: shape variations associated with gummivory in the family Cheirogaleidae. Ann Anat 186, 495-501.
53. Desmet VJ (1992) Congenital diseases of intrahepatic bile ducts: variations on the theme 'ductal plate malformation'. Hepatology 16, 1069-1083.
54. Ghent CN, Bloomer JR, Klatskin G (1977) Elevations in skin tissue levels of bile acids in human cholestasis: relation to serum levels and to pruritus. Gastroenterology 73, 1125-1130.
55. Ghent CN (1987) Pruritus of cholestasis is related to effects of bile salts on the liver, not the skin. Am J Gastroenterol 82, 117-118.
56. Bergasa NV, Jones EA (1995) The pruritus of cholestasis: potential pathogenic and therapeutic implications of opioids. Gastroenterology 108, 1582-1588.
57. Jones EA, Bergasa NV (1990) The pruritus of cholestasis: from bile acids to opiate agonists. Hepatology 11, 884-887.
58. Poupon RE, Chretien Y, Chazouilleres O et al. (2004) Quality of life in patients with primary biliary cirrhosis. Hepatology 40, 489-494.
59. Swain MG, Maric M (1997) Improvement in cholestasis-associated fatigue with a serotonin receptor agonist using a novel rat model of fatigue assessment. Hepatology 25, 291-294.
60. Hay JE (1995) Bone disease in cholestatic liver disease. Gastroenterology 108, 276-283.
61. Guichelaar MM, Malinchoc M, Sibonga J et al. (2002) Bone metabolism in advanced cholestatic liver disease: analysis by bone histomorphometry. Hepatology 36, 895-903.
62. Janes CH, Dickson ER, Okazaki R et al. (1995) Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest 95, 2581-2586.
63. Xu Q, Lu Z, Zhang X (2002) A novel role of alkaline phosphatase in protection from immunological liver injury in mice. Liver 22, 8-14.
64. Cooper JF, Brand EJ (1988) Symptomatic sclerosing cholangitis in patients with a normal alkaline phosphatase: two case reports and a review of the literature. Am J Gastroenterol 83, 308-311.
65. Whitfield JB (2001) Gamma glutamyl transferase. Crit Rev Clin Lab Sci 38, 263-355.
66. Jansen PL, Muller M, Sturm E (2001) Genes and cholestasis. Hepatology 34, 1067-1074.
67. Walker IA, Nelson-Piercy C, Williamson C (2002) Role of bile acid measurement in pregnancy. Ann Clin Biochem 39, 105-113.
68. Heathcote EJ (2000) Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology 31, 1005-1013.
69. Heathcote J (1997) Autoimmune cholangitis. Gut 40, 440-442.
70. Chazouilleres O, Wendum D, Serfaty L et al. (1998) Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 28, 296-301.
71. Vleggaar FP, van Buuren HR, Zondervan PE et al. (2001) Jaundice in non-cirrhotic primary biliary cirrhosis: the premature ductopenic variant. Gut 49, 276-281.
72. Lee YM, Kaplan MM (1995) Primary sclerosing cholangitis. N Engl J Med 332, 924-933.
73. Wee A, Ludwig J (1985) Pericholangitis in chronic ulcerative colitis: primary sclerosing cholangitis of the small bile ducts? Ann Intern Med 102, 581-587.
74. Roulot D, Degott C, Chazouilleres O et al. (2004) Vascular involvement of the liver in Turner's syndrome. Hepatology 39, 239-247.
75. Bognel C, Degott C, Rougier P et al. (1989) [Anatomo-pathologic study of hepatic toxicity in intra-arterial hepatic chemotherapy]. Gastroenterol Clin Biol 13, 125-131.
76. Biour M, Ben Salem C, Chazouilleres O et al. (2004) [Drug-induced liver injury: fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. Gastroenterol Clin Biol 28, 720-759.
77. Levy C, Lindor KD (2003) Drug-induced cholestasis. Clin Liver Dis 7, 311-330.
78. Velayudham LS, Farrell GC (2003) Drug-induced cholestasis. Expert Opin Drug Saf 2, 287-304.
79. Benichou C (1990) Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 11, 272-276.
80. Ryley NG, Fleming KA, Chapman RW (1995) Focal destructive cholangiopathy associated with amoxycillin/clavulanic acid (Augmentin). J Hepatol 23, 278-282.
81. Degott C, Feldmann G, Larrey D et al. (1992) Drug-induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia. Hepatology 15, 244-251.
82. Aithal PG, Day CP (1999) The natural history of histologically proved drug induced liver disease. Gut 44, 731-735.
83. Rosmorduc O, Hermelin B, Poupon R (2001) MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis. Gastroenterology 120, 1459-1467.
84. Dixon PH, Weerasekera N, Linton KJ et al. (2000) Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy: evidence for a defect in protein trafficking. Hum Mol Genet 9, 1209-1217.
85. Lucena JF, Herrero JI, Quiroga J et al. (2003) A multidrug resistance 3 gene mutation causing cholelithiasis, cholestasis of pregnancy, and adulthood biliary cirrhosis. Gastroenterology 124, 1037-1042.
86. Garcia-Tsao G, Korzenik JR, Young L et al. (2000) Liver disease in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 343, 931-936.
87. Bloomer JR, Phillips MJ, Davidson DL et al. (1975) Hepatic disease in erythropoietic protoporphyria. Am J Med 58, 869-882.
88. Moseley RH (2004) Sepsis and cholestasis. Clin Liver Dis 8, 83-94.
89. Sikuler E, Guetta V, Keynan A et al. (1989) Abnormalities in bilirubin and liver enzyme levels in adult patients with bacteremia. A prospective study. Arch Intern Med 149, 2246-2248.
90. de Kerguenec C, Hillaire S, Molinie V et al. (2001) Hepatic manifestations of hemophagocytic syndrome: a study of 30 cases. Am J Gastroenterol 96, 852-857.
91. Ben-Ari Z, Pappo O, Mor E (2003) Intrahepatic cholestasis after liver transplantation. Liver Transpl 9, 1005-1018.
92. Te HS (2004) Cholestasis in HIV-infected patients. Clin Liver Dis 8, 213-228, viii-ix.
93. Ludwig J (1998) Idiopathic adulthood ductopenia: an update. Mayo Clin Proc 73, 285-291.
94. Sapey T, Turlin B, Canva-Delcambre V et al. (1999) [Importance of liver puncture biopsy and endoscopic retrograde cholangiography in patients with chronic anicteric unexplained cholestasis. A retrospective study in 79 patients]. Gastroenterol Clin Biol 23, 178-185.
95. Hempfling W, Dilger K, Beuers U (2003) Systematic review: ursodeoxycholic acid-adverse effects and drug interactions. Aliment Pharmacol Ther 18, 963-972.
96. Schliess F, Kurz AK, vom Dahl S et al. (1997) Mitogen-activated protein kinases mediate the stimulation of bile acid secretion by tauroursodeoxycholate in rat liver. Gastroenterology 113, 1306-1314.
97. Jazrawi RP, de Caestecker JS, Goggin PM et al. (1994) Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid. Gastroenterology 106, 134-142.
98. Fickert P, Zollner G, Fuchsbichler A et al. (2001) Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. Gastroenterology 121, 170-183.
99. Zollner G, Fickert P, Fuchsbichler A et al. (2003) Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. J Hepatol 39, 480-488.
100. Kurz AK, Block C, Graf D et al. (2000) Phosphoinositide 3-kinasedependent Ras activation by tauroursodesoxycholate in rat liver. Biochem J 350(Pt 1), 207-213.
101. Beuers U, Boyer JL, Paumgartner G (1998) Ursodeoxycholic acid in cholestasis: potential mechanisms of action and therapeutic applications. Hepatology 28, 1449-1453.
102. Marschall HU, Wagner M, Zollner G et al. (2005) Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 129, 476-485.
103. Nathanson MH, Burgstahler AD, Masyuk A et al. (2001) Stimulation of ATP secretion in the liver by therapeutic bile acids. Biochem J 358, 1-5.
104. Prieto J, Garcia N, Marti-Climent JM et al. (1999) Assessment of biliary bicarbonate secretion in humans by positron emission tomography. Gastroenterology 117, 167-172.
105. Heuman DM, Bajaj RS, Lin Q (1996) Adsorption of mixtures of bile salt taurine conjugates to lecithin-cholesterol membranes: implications for bile salt toxicity and cytoprotection. J Lipid Res 37, 562-573.
106. Botla R, Spivey JR, Aguilar H et al. (1995) Ursodeoxycholate (UDCA) inhibits the mitochondrial membrane permeability transition induced by glycochenodeoxycholate: a mechanism of UDCA cytoprotection. J Pharmacol Exp Ther 272, 930-938.
107. Rodrigues CM, Fan G, Ma X et al. (1998) A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest 101, 2790-2799.
108. Que FG, Phan VA, Phan VH et al. (1999) GUDC inhibits cytochrome c release from human cholangiocyte mitochondria. J Surg Res 83, 100-105.
109. Hillaire S, Boucher E, Calmus Y et al. (1994) Effects of bile acids and cholestasis on major histocompatibility complex class I in human and rat hepatocytes. Gastroenterology 107, 781-788.
110. Lazaridis KN, Gores GJ, Lindor KD (2001) Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. J Hepatol 35, 134-146.
111. Paumgartner G, Beuers U (2002) Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 36, 525-531.
112. Poupon RE, Lindor KD, Cauch-Dudek K et al. (1997) Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 113, 884-890.
113. Kondrackiene J, Beuers U, Kupcinskas L (2005) Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology 129, 894-901.
114. Palma J, Reyes H, Ribalta J et al. (1997) Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. J Hepatol 27, 1022-1028.
115. Lindor KD (1997) Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 336, 691-695.
116. Harnois DM, Angulo P, Jorgensen RA et al. (2001) High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 96, 1558-1562.
117. Mitchell SA, Bansi DS, Hunt N et al. (2001) Preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 121, 900-907.
118. Tung BY, Emond MJ, Haggitt RC et al. (2001) Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 134, 89-95.
119. Colombo C, Battezzati PM, Podda M et al. (1996) Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis. Hepatology 23, 1484-1490.
120. Jacquemin E, Hermans D, Myara A et al. (1997) Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis. Hepatology 25, 519-523.
121. Essell JH, Schroeder MT, Harman GS et al. (1998) Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 128, 975-981.
122. Ghent CN, Carruthers SG (1988) Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology 94, 488-493.
123. Bachs L, Pares A, Elena M et al. (1992) Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 102, 2077-2080.
124. Bergasa NV, Alling DW, Talbot TL et al. (1995) Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. Ann Intern Med 123, 161-167.
125. Bergasa NV, Schmitt JM, Talbot TL et al. (1998) Open-label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology 27, 679-684.
126. Wolfhagen FH, Sternieri E, Hop WC et al. (1997) Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebocontrolled study. Gastroenterology 113, 1264-1269.
127. Theal JJ, Toosi MN, Girlan L et al. (2005) A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue. Hepatology 41, 1305-1312.
128. Hofmann AF, Zakko SF, Lira M et al. (2005) Novel biotransformation and physiological properties of norursodeoxycholic acid in humans. Hepatology 42, 1391-1398.
129. Fickert P, Wagner M, Marschall HU et al. (2006) 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 130, 465-481.
130. Demeilliers C, Jacquemin E, Barbu V et al. (2006) Altered hepatobiliary gene expressions in PFIC1: ATP8B1 gene defect is associated with CFTR down-regulation. Hepatology 43, 1125-1134.
131. Fiorucci S, Antonelli E, Rizzo G et al. (2004) The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 127, 1497-1512.
132. McCarthy TC, Li X, Sinal CJ (2005) Vitamin D receptor-dependent regulation of colon multidrug resistance-associated protein 3 gene expression by bile acids. J Biol Chem 280, 23232-23242.